Business Insider

AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive multiple sclerosis with no requirement to ...

AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the ...
ALS News Today

AB Science adds new biomarker to Phase 3 masitinib ALS clinical trial

AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical trial.
WRIC

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

AB Science SA (Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the ...
Business Insider

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
Morningstar

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection ...

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
Yahoo Finance

Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)

Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech ...
Seeking Alpha

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
Nasdaq

AB Science (ENXTPA:AB) Price Target Increased by 22.25% to 4.31

The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...
Taiwan News

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors

AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast ...
Business Wire

Skuldtech and AB Science announce the identification of new predictive markers for pancreatic cancer survival associated with masitinib treatment

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Skuldtech, a genomic and pharmacogenomic company specialized in developing diagnostic tests, and AB Science (NYSE Euronext – FR0010557264 – AB), ...
Yahoo Finance

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB Science SA (Euronext - FR0010557264 - AB) announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral ...